查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2067812

2026-2034年全球獲得性血友病治療市場規模、佔有率、趨勢和成長分析報告

Global Acquired Hemophilia Therapeutics Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 230 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球獲得性血友病治療市場規模預計將從2025年的85.5億美元成長至2034年的154.2億美元，並預計在2026年至2034年間以6.77%的複合年成長率成長。該市場成長較為溫和，主要得益於人們對後天性血友病（一種由自身抗體對抗凝血因子引起的罕見出血性疾病）的認知不斷提高以及診斷率的上升。醫療專業人員對該疾病意識提升和治療方案的改進也促進了市場發展。此外，由於患者能夠更便捷地獲得專業醫療服務，因此病患管理水準也得到了進一步提升。

關鍵成長要素包括診斷檢測技術的進步、標靶治療的普及以及醫療保健投資的增加。醫生們正在採用先進的治療方法，旨在抑制出血事件並解決潛在的免疫反應。專注於罕見疾病管理的研究活動也促進了創新治療方案的推出。

前景依然光明，這得益於醫療體系內罕見疾病項目的加強以及製藥公司持續研發針對性治療方法。生物製藥和個人化醫療的進步有望改善治療效果。意識提升和持續的臨床研究也有望推動獲得性血友病治療市場的持續成長。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為指定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別預期的未來趨勢。

區域分析：我們全面檢驗主要地理區域的市場表現，識別高成長領域和區域趨勢，並深入了解區域市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，從而更有效地支援策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球獲得性血友病治療市場：依療法分類

  • 市場分析、洞察與預測
  • 按需治療（凝血因子、替代療法、去氨加壓素和其他按需療法）
  • 預防性治療（凝血因子替代療法、基因療法和其他預防性療法）

第5章：全球獲得性血友病治療市場：按類型分類

  • 市場分析、洞察與預測
  • A型血友病
  • B型血友病
  • C型血友病
  • 其他

第6章 全球獲得性血友病治療市場：依最終用戶分類

  • 市場分析、洞察與預測
  • 醫院
  • 診所
  • 其他

第7章 全球獲得性血友病治療市場：按地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第8章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第9章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Pfizer Inc
    • Roche Holding AG
    • Bayer AG
    • Novartis AG
    • Bristol-Myers Squibb Company
    • Sanofi SA
    • GlaxoSmithKline Plc
    • Takeda PharmaceuticalCompany Limited
    • Amgen Inc
    • Novo Nordisk A/S
    • Baxter Healthcare Corporation
    • Teva Pharmaceutical Industries Ltd
    • Mylan NV
    • Biogen Inc
簡介目錄
Product Code: VMR11216608

The global acquired hemophilia therapeutics market size is expected to reach USD 15.42 Billion in 2034 from USD 8.55 Billion in 2025, growing at a CAGR of 6.77 during 2026-2034.This market has experienced gradual growth due to increasing recognition and diagnosis of acquired hemophilia, a rare bleeding disorder caused by the development of autoantibodies against clotting factors. Improved awareness among healthcare professionals and advancements in treatment protocols have supported market development. Expanding access to specialized care has further enhanced patient management.

Key growth drivers include improvements in diagnostic testing, increasing availability of targeted therapies, and growing healthcare investments. Physicians are adopting advanced treatment approaches aimed at controlling bleeding episodes and addressing underlying immune responses. Research efforts focused on rare disease management have also contributed to the introduction of innovative therapeutic options.

Future prospects remain positive as healthcare systems strengthen rare disease programs and pharmaceutical companies continue developing specialized treatments. Advances in biologic therapies and personalized medicine are expected to improve treatment outcomes. Increased patient awareness and ongoing clinical research will likely support sustained growth in the acquired hemophilia therapeutics market.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Treatment

  • On-Demand (Clotting Factor, Replacement Therapy, Desmopressin, Other On-Demand Treatments)
  • Prophylaxis (Clotting Factor Replacement Therapy, Gene Therapy, Other Prophylaxis Treatments)

By Type

  • Hemophilia A
  • Hemophilia B
  • Hemophilia C
  • Other

By End User

  • Hospitals
  • Clinic
  • Other

COMPANIES PROFILED

  • Pfizer Inc., Roche Holding AG, Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Sanofi SA, GlaxoSmithKline plc, Takeda PharmaceuticalCompany Limited, Amgen Inc., Novo Nordisk A/S, Baxter Healthcare Corporation, Teva Pharmaceutical Industries Ltd., Mylan NV, Biogen Inc.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL ACQUIRED HEMOPHILIA THERAPEUTICS MARKET: BY TREATMENT 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Treatment
  • 4.2. On-Demand (Clotting Factor, Replacement Therapy, Desmopressin, Other On-Demand Treatments) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Prophylaxis (Clotting Factor Replacement Therapy, Gene Therapy, Other Prophylaxis Treatments) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ACQUIRED HEMOPHILIA THERAPEUTICS MARKET: BY TYPE 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Type
  • 5.2. Hemophilia A Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Hemophilia B Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Hemophilia C Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ACQUIRED HEMOPHILIA THERAPEUTICS MARKET: BY END USER 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast End User
  • 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Clinic Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ACQUIRED HEMOPHILIA THERAPEUTICS MARKET: BY REGION 2022-2034 (USD MN)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.2.1 By Treatment
    • 7.2.2 By Type
    • 7.2.3 By End User
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.3.1 By Treatment
    • 7.3.2 By Type
    • 7.3.3 By End User
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Russia
    • 7.3.9 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.4.1 By Treatment
    • 7.4.2 By Type
    • 7.4.3 By End User
    • 7.4.4 India
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 Australia
    • 7.4.8 South East Asia
    • 7.4.9 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.5.1 By Treatment
    • 7.5.2 By Type
    • 7.5.3 By End User
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.6.1 By Treatment
    • 7.6.2 By Type
    • 7.6.3 By End User
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL ACQUIRED HEMOPHILIA THERAPEUTICS INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 Pfizer Inc
    • 9.2.2 Roche Holding AG
    • 9.2.3 Bayer AG
    • 9.2.4 Novartis AG
    • 9.2.5 Bristol-Myers Squibb Company
    • 9.2.6 Sanofi SA
    • 9.2.7 GlaxoSmithKline Plc
    • 9.2.8 Takeda PharmaceuticalCompany Limited
    • 9.2.9 Amgen Inc
    • 9.2.10 Novo Nordisk A/S
    • 9.2.11 Baxter Healthcare Corporation
    • 9.2.12 Teva Pharmaceutical Industries Ltd
    • 9.2.13 Mylan NV
    • 9.2.14 Biogen Inc